
News|Articles|June 18, 2025
Pharmacy Practice in Focus: Oncology
- June 2025
- Volume 7
- Issue 4
Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia
Fact checked by: Luke Halpern, Associate Editor
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Advertisement
Advertisement
Alan Flores, PharmD, Jose Tinajero, PharmD, BCOP, and Dat Ngo, PharmD, BCOP, are set to present their abstract "Sequencing of Liposomal Daunorubicin/Cytarabine (Vyxeos) vs Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia" at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20. The abstract explores treatment sequencing in patients with secondary acute myeloid leukemia (sAML) who received both liposomal daunorubicin/cytarabine and hypomethylating agents with venetoclax during their care.
Related to this article

A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.

In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

An analysis of 40 economic studies found PCV20 and PCV21 outperformed older strategies, while low uptake and racial gaps limited the benefit of vaccination.

Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.
Advertisement
Advertisement
